Sintilimab versus pembrolizumab in monotherapy or combination with chemotherapy as first-line therapy for advanced non–small cell lung cancer: Results from phase 2, randomized clinical trial (CTONG1901)

MLA

Si-Yang Maggie Liu, et al. “Sintilimab versus Pembrolizumab in Monotherapy or Combination with Chemotherapy as First-Line Therapy for Advanced Non–small Cell Lung Cancer: Results from Phase 2, Randomized Clinical Trial (CTONG1901).” Journal of Clinical Oncology, vol. 40, June 2022, p. 9032. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........b7bc58988ea599d007526a5307ff1f2d&authtype=sso&custid=ns315887.

APA

Si-Yang Maggie Liu, Qing Zhou, Hong-Hong Yan, Gan Bin, Ming-Yi Yang, Jia-Yi Deng, Hai-Yan Tu, Xuchao Zhang, Jian Su, Jinji Yang, & Yi-Long Wu. (2022). Sintilimab versus pembrolizumab in monotherapy or combination with chemotherapy as first-line therapy for advanced non–small cell lung cancer: Results from phase 2, randomized clinical trial (CTONG1901). Journal of Clinical Oncology, 40, 9032.

Chicago

Si-Yang Maggie Liu, Qing Zhou, Hong-Hong Yan, Gan Bin, Ming-Yi Yang, Jia-Yi Deng, Hai-Yan Tu, et al. 2022. “Sintilimab versus Pembrolizumab in Monotherapy or Combination with Chemotherapy as First-Line Therapy for Advanced Non–small Cell Lung Cancer: Results from Phase 2, Randomized Clinical Trial (CTONG1901).” Journal of Clinical Oncology 40 (June): 9032. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........b7bc58988ea599d007526a5307ff1f2d&authtype=sso&custid=ns315887.